603716.SHG Wuhan Thalys Med Tech Co Ltd
- Market cap
- CNY 3.51B
- P/E
- -
- P/B
- 3.17x
- ROE
- -6.9%
- Dividend yield
- 0.53%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 603716.SHG undervalued?
Graham numberThe Graham number of Wuhan Thalys Med Tech Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Wuhan Thalys Med Tech Co Ltd fundamental analysis
No fundamental analysis for Wuhan Thalys Med Tech Co Ltd yet.
Wuhan Thalys Med Tech Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Wuhan Thalys Med Tech Co Ltd
Thalys Medical Technology Group Corporation provides medical integrated operation and management services in China. The company offers fully automated immunofluorescence analyzer; coagulation reagent; COVID-19 test kit; line blot1 fully automated immunoblotting instrument; and flow products. It also provides automated coagulation analyzer; automated immunoassay system; automated biochemical analysis system; automated chemiluminescence immunoassay system; and blood analyzer. …
Full company profileWuhan Thalys Med Tech Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Wuhan Thalys Med Tech Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 627M | 921M | 1.32B | 1.83B | 2.13B | 2.60B | 2.31B | 2.01B | 1.81B | 1.08B | 653M |
| Gross Profit | 218M | 310M | 416M | 520M | 487M | 543M | 449M | 390M | 329M | 240M | 154M |
| Operating Income | 94.6M | 139M | 159M | 187M | 117M | -16.2M | -149M | -180M | -142M | -58.0M | -78.5M |
| EBITDA | 143M | 198M | 247M | 300M | 243M | 133M | -30.9M | -63.8M | -55.5M | -74.8M | -78.3M |
| Net Income | 68.9M | 93.8M | 94.2M | 110M | 57.6M | -49.5M | -154M | -159M | -209M | -207M | -74.7M |
| EPS | 0.39 | 0.53 | 0.49 | 0.56 | 0.29 | -0.25 | -0.79 | -0.82 | -1.09 | -0.99 | -0.33 |
| Balance Sheet | |||||||||||
| Total Assets | 1.09B | 1.57B | 2.58B | 3.01B | 3.91B | 4.29B | 3.95B | 3.34B | 2.83B | 1.80B | 1.53B |
| Total Liabilities | 233M | 566M | 957M | 1.39B | 2.10B | 2.55B | 2.45B | 2.03B | 1.87B | 898M | 512M |
| Shareholders' Equity | 844M | 933M | 1.52B | 1.49B | 1.65B | 1.56B | 1.40B | 1.21B | 934M | 945M | 1.08B |
| Cash & Short-term Investments | 354M | 196M | 703M | 510M | 662M | 486M | 395M | 279M | 209M | 131M | 76.6M |
| Total Debt | 168M | 339M | 690M | 882M | 1.40B | 1.62B | 1.44B | 1.04B | 900M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -17.0M | -63.3M | -63.8M | 93.9M | 9.94M | -134M | 28.1M | 126M | 99.6M | -37.8M | - |
| Capital Expenditure | 69.0M | 116M | 119M | 96.5M | 128M | 60.2M | 54.6M | 40.8M | 23.2M | 5.72M | 2.47M |
| Free Cash Flow | -86.1M | -179M | -182M | -2.57M | -118M | -194M | -26.5M | 85.1M | 76.4M | -43.5M | -63.3M |
| Ratios | |||||||||||
| ROE | 8.2% | 10.1% | 6.2% | 7.4% | 3.5% | -3.2% | -11.0% | -13.1% | -22.4% | -21.9% | -6.9% |
| ROA | 6.3% | 6.0% | 3.6% | 3.7% | 1.5% | -1.2% | -3.9% | -4.7% | -7.4% | -11.5% | -4.9% |
| Net Profit Margin | 11.0% | 10.2% | 7.1% | 6.0% | 2.7% | -1.9% | -6.7% | -7.9% | -11.6% | -19.2% | -11.4% |
| Debt to Equity | 0.20x | 0.36x | 0.45x | 0.59x | 0.85x | 1.04x | 1.02x | 0.86x | 0.96x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Wuhan Thalys Med Tech Co Ltd dividends
- Dividend yield
- 0.53%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 18, 2020
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 18.6M | 0.09 | - |
| 2024 | CNY 59.9M | 0.31 | - |
| 2023 | CNY 38.8M | 0.20 | - |
| 2022 | CNY 52.3M | 0.27 | - |
| 2021 | CNY 49.5M | 0.25 | - |
| 2020 | CNY 15.9M | 0.08 | 27.6% |
| 2019 | CNY 50.1M | 0.25 | 45.4% |
| 2018 | CNY 37.2M | 0.19 | 39.5% |
| 2017 | CNY 14.7M | 0.08 | 15.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2.5:1 on Apr 25, 2018.
Who owns Wuhan Thalys Med Tech Co Ltd
- Insiders 20.50%
- Institutions 2.60%
- Public & others 76.89%
- Shares outstanding 226M
- Free float 203M
Wuhan Thalys Med Tech Co Ltd company profile
- Company name
- Wuhan Thalys Med Tech Co Ltd
- Ticker
- 603716.SHG
- ISIN
- CNE1000030C3
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1,045
- Fiscal year end
- December
- Address
- No. 1310 Jinshan Avenue, Wuhan, China, 430040
- Phone
- 86 27 8338 6378
- Website
- thalys.net.cn
About Wuhan Thalys Med Tech Co Ltd
Thalys Medical Technology Group Corporation provides medical integrated operation and management services in China. The company offers fully automated immunofluorescence analyzer; coagulation reagent; COVID-19 test kit; line blot1 fully automated immunoblotting instrument; and flow products. It also provides automated coagulation analyzer; automated immunoassay system; automated biochemical analysis system; automated chemiluminescence immunoassay system; and blood analyzer. The company was formerly known as Thalys Medical Technology Inc. and changed its name to Thalys Medical Technology Group Corporation in September 2020. Thalys Medical Technology Group Corporation was founded in 2004 and is headquartered in Wuhan, China.
Wuhan Thalys Med Tech Co Ltd management
7- Mr. Zheng WangGM & Director · born 1967
- Ms. Yan ShenChief Financial Officer · born 1977
- Ms. Li FanDeputy GM, Secretary of the Board & Director · born 1981
- Mr. Yi LuDeputy GM & Employee Director · born 1981
- Si Yan HuangAccounting Supervisor
- Mr. Jun SunAdministrative Director · born 1969
- Mr. Feng LiuGM of SPD Business & Regional Inspection Center Business Department and Deputy GM · born 1975